

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (BAP)
For the February 2023 DoD Pharmacy and Therapeutics Committee Meetings
April 4, 2023 at 10:00 AM Eastern Daylight Saving Time***

Virtual Meeting

- **Administrative Meeting: 9:00 AM – 9:45 AM Eastern Daylight Saving Time (General session starts at 10:00 AM Eastern Daylight Saving Time)**
- **Roll Call**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4 (complete exclusion) candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the February 2023 meeting:

- **Drug Class Reviews**

- *Insomnia Agents*
 - *Dual Orexin Receptor Antagonists Subclass*
- *Androgens-Anabolic Steroids*
 - *Testosterone Replacement Therapies Subclass*
- *Nephrology Agents Miscellaneous*

- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**

- *dextroamphetamine transdermal system (Xelstrym) – Attention deficit hyperactivity disorder (ADHD) Stimulant*
- *dextromethorphan hydrobromide/bupropion hydrochloride (Auvelity) – Antidepressants and non-opioid pain syndrome agents*
- *furosemide SC injection (Furoscix) – Diuretic*

Furoscix was recommended for Tier 4 placement as it has little to no clinical benefit relative to other diuretics, and the needs of TRICARE beneficiaries are met by alternative agents. Formulary alternatives include furosemide, bumetanide, ethacrynic acid and torsemide tablets.
- *lutibatinib (Lytgobi) – Oncological agent for intra-hepatic cholangiocarcinoma*
- *insulin glargine (Basaglar Tempo Pen) – Basal insulin; note that as part of this*

recommendation the Basaglar TEMPO pen will be non-step-preferred

- *insulin lispro (Humalog Tempo Pen) – Rapid acting insulin. Note that as part of this recommendation the Humalog Tempo pen will be step-preferred.*
- *insulin lispro-aabc (Lyumjev Tempo Pen) – Rapid acting insulin; note that as part of this recommendation the Lyumjev TEMPO pen will be non-step-preferred*

Note that for the three TEMPO pens (Basaglar, Lyumjev and Humalog) the actual Tempo Smart button and app are not a covered TRICARE pharmacy benefit at this time.

- *leuprolide acetate depot injection (no brand name) - Luteinizing hormone-releasing hormone (LHRH) agonists-antagonists for prostate cancer*
- *levothyroxine sodium 150 mcg/5 mL oral solution (Ermeza) – Thyroid agent*
- *olutasidenib (Rezlidhia) – Oncological agent for acute myeloid leukemia (AML) with isocitrate dehydrogenase-1 (IDH1) mutation*
- *pegfilgrastim-pbbk (Fylnetra) – White Blood Cell (WBC) stimulants – pegfilgrastims. Note that as part of this recommendation, Fylnetra will be non-step-preferred*
- *posaconazole DR oral suspension (Noxafil Powdermix Kit) – Antifungal for prophylaxis of invasive Aspergillus and Candida*
- *sodium phenylbutyrate/sodium taurursodiol powder for oral suspension (Relyvrio) – miscellaneous neurological agent for amyotrophic lateral sclerosis (ALS)*

➤ **Utilization Management Issues**

- **Prior Authorization Criteria—New Manual PA Criteria and Formulary Status**
 - *Mifepristone 200 mg tablet (Mifeprex)*
- **New Manual PA Criteria for Newly Approved Drugs Not Subject to 32 CFR 199.21(g)(5)**
 - *Antigout Agent—allopurinol 200 mg tablet*
 - *Skeletal Muscle Relaxants and Combinations—methocarbamol 1000 mg*
- **Prior Authorization Criteria—Updated PA Criteria for New FDA-Approved Indications**
 - *Atopy Agents—dupilumab (Dupixent)*
 - *Atopy Agents: Oral Janus Kinase Inhibitor (JAK-1)—upadacitinib (Rinvoq)*

- *Neurological Agents Miscellaneous—amifampridine (Firdapse)*
- *Oncological Agents—elpercatinib (Retevmo)*
- *Oncological Agents: Melanoma—cobimetinib (Cotellic)*
- *Osteoporosis Agents: Parathyroid Hormone Analogs—abaloparatide (Tymlos)*
- **Prior Authorization Criteria—Updated PA Criteria for Safety Information**
 - *Oral Oncologic Agents: Ovarian Cancer—niraparib (Zejula)*
- **Prior Authorization Criteria—Updated PA Criteria for Reasons Other Than New Indications**
 - *Insulins: Miscellaneous Insulin Devices*
 - *Omnipod 5*
 - *Omnipod DASH (4) and Omnipod 3*
 - *Targeted Immunomodulatory Biologics: Tumor Necrosis Factor Inhibitors—adalimumab*
 - *adalimumab plaque psoriasis update*
 - *biosimilars to Humira*
- **Prior Authorization Criteria—Updated PA Criteria for Weight Loss Drugs**
 - *liraglutide (Saxenda) Insulins*
 - *phentermine/ topiramate ER (Qsymia)*
 - *semaglutide (Wegovy)*

➤ **Authorized Generic PA Criteria**

- *Sleep Disorders: Wakefulness Promoting Agent: sodium oxybate (Xyrem)*

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will concur or non-concur on the recommendations of the P&T Committee concerning the establishment of the UF and subsequent recommended changes. The Panel will provide comments on their vote as directed by the Panel Chairman. Comments to the Director, DHA, or their designee will be considered before making a final UF decision.